|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||84.98 - 84.98|
|52-week range||84.98 - 84.98|
|Beta (5Y monthly)||3.14|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.